Keywords: Xarelto, Johnosn & Johnosn, Bayer, USA, FDA, Briefing documents, Acute coronary syndrome

FDA staffers basically back Xarelto for ACS but identify missing data in study

Article | 22 May 2012

Print This

The US Food and Drug Administration advisory panelists due to revue Johnson & Johnson (NYSE: JNJ) and Bayer’s ( ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in